2022-Alzheimer's Association International Conference
Title: Targeting the Correct Population for Trials: A Post-hoc Analysis of Trial of Solanezumab for Mild Dementia Due to Alzheimer’s disease.
Authors: Ali Ezzati, MD; Kellen K. Petersen, PhD, Bhargav Nallapu, PhD, Christian Habeck, PhD; Charles Hall, PhD; Christos Davatzikos, PhD; David Wolk, PhD; & Richard B. Lipton, MD
Disclaimer: Neurodiction LLC, has no relationship with this work. The post is for informational purposes only.